423 related articles for article (PubMed ID: 29998217)
1. Bispecific antibodies in cancer immunotherapy.
Dahlén E; Veitonmäki N; Norlén P
Ther Adv Vaccines Immunother; 2018 Feb; 6(1):3-17. PubMed ID: 29998217
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
You G; Won J; Lee Y; Moon D; Park Y; Lee SH; Lee SW
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358141
[TBL] [Abstract][Full Text] [Related]
3. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
4. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.
Kobold S; Pantelyushin S; Rataj F; Vom Berg J
Front Oncol; 2018; 8():285. PubMed ID: 30090763
[TBL] [Abstract][Full Text] [Related]
6. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
[TBL] [Abstract][Full Text] [Related]
8. [Immuno-Oncology: A Brief Overview].
Kobold S; Krackhardt A; Schlösser H; Wolf D
Dtsch Med Wochenschr; 2018 Jul; 143(14):1006-1013. PubMed ID: 30005434
[TBL] [Abstract][Full Text] [Related]
9. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
10. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Koopmans I; Hendriks D; Samplonius DF; van Ginkel RJ; Heskamp S; Wierstra PJ; Bremer E; Helfrich W
Oncoimmunology; 2018; 7(8):e1466016. PubMed ID: 30221065
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies in cancer immunotherapy.
Chen S; Li J; Li Q; Wang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
[TBL] [Abstract][Full Text] [Related]
12. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
14. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
[TBL] [Abstract][Full Text] [Related]
15. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X; Ning W; Liu H; Liu X; Luo W; Xia N
Acta Pharm Sin B; 2024 Jun; 14(6):2361-2377. PubMed ID: 38828136
[TBL] [Abstract][Full Text] [Related]
16. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
17. Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer.
Bulaon CJI; Khorattanakulchai N; Rattanapisit K; Sun H; Pisuttinusart N; Phoolcharoen W
Planta Med; 2024 Apr; 90(4):305-315. PubMed ID: 38373705
[TBL] [Abstract][Full Text] [Related]
18. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
19. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
